Search Results

Keywords: epidiolex

Denmark medical cannabis sales post a positive quarter thanks to Epidiolex

January 7, 2021

Sales of medical marijuana in Denmark posted healthy gains in the third quarter of 2020, coinciding with the launch of GW Pharmaceuticals’ cannabis drug Epidiolex. Overall sales of all medial cannabis products grew from about 13 million Danish Krones ($2 million) in the second quarter to almost 16 million Danish Krones in the third quarter, […]

Read More

Epidiolex maker GW Pharma reports record quarterly revenue of $137 million

November 4, 2020

United Kingdom-based GW Pharmaceuticals posted higher revenue in the quarter ended Sept. 30, largely driven by U.S. sales of its cannabidiol medicine Epidiolex. GW’s total revenue for the third quarter reached $137.1 million, about 16% more than the previous quarter’s $121.3 million. Epidiolex sales in the United States accounted for 87% of the company’s overall […]

Read More

Epidiolex maker GW Pharma turns in flat second quarter on pandemic impact

August 7, 2020

United Kingdom-based GW Pharmaceuticals posted marginal revenue growth in the second quarter over the previous quarter, citing challenges stemming from the COVID-19 pandemic. GW reported revenue of $121.3 million for the quarter ended June 30 – about the same as the previous period. GW’s quarterly net loss rose slightly to $8.8 million. By product, Epidiolex […]

Read More

DEA removes cannabis drug Epidiolex from controlled substances list

April 7, 2020

Epidiolex, the only plant-derived cannabis drug approved by the U.S. Food and Drug Administration, is no longer considered a controlled substance, providing a boost to its manufacturer’s stock price. GW Pharmaceuticals, a biopharmaceutical company based in London, saw its stock go up 5.9% on Tuesday, one day after the U.S. Drug Enforcement Administration said it […]

Read More

Australia expedites review of medical cannabis product Epidiolex

January 30, 2020 · Updated February 3, 2020

The only medical cannabis product in the Australian Register of Therapeutic Goods might soon be joined by another. Australian health regulators quietly gave Epidiolex, a cannabidiol medication, orphan designation and priority review status in late 2019. The designations allow the Therapeutic Goods Administration to waive application and evaluation fees, as well as expedite its assessment […]

Read More

European Commission approves Epidiolex marketing authorization, GW Pharmaceuticals says

September 23, 2019

The European Commission granted marketing authorization to Epidyolex, the trade name in Europe for Epidiolex, GW Pharmaceuticals announced Monday. In June 2018, the U.S. Food and Drug Administration approved Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older. The CBD-based medicine was greenlighted in Europe […]

Read More

Epidiolex, Sativex maker GW Pharmaceuticals reports Q1 revenue, loss improvement

May 6, 2019

United Kingdom-based GW Pharmaceuticals showed revenue of $39.2 million for the quarter ended March 31, 2019, compared with $3 million in the same period a year ago. The maker of cannabis-derived medications, including Sativex and Epidiolex, recorded a net loss for the quarter of $50.1 million compared with a year-ago net loss of $69.5 million. […]

Read More

Study of a standardized THC product may lead to medical use

April 26, 2021

Other than a few FDA-approved cannabinoid-based medications—Sativex, Marinol, and Epidiolex—cannabis products meant for medical use are recreational cannabis products that may lack rigorous safety, dosing, and efficacy studies essential for medical drugs. Numerous clinical trials for cannabinoid-based medicines are underway, including a recently published Phase 1 multiple-dose study of a standardized THC-dominant product. Canopy Growth […]

Read More